Below contains a listing of recent congress presentations, except those published in manuscript form, related to our work in bone health.
2023
Cost-Effectiveness Analysis of Sequential Treatment With Abaloparatide Followed by Alendronate in US Women and Men With Multiple Previous Fractures
Hiligsmann, PhD; Stuart S. Silverman, MD; Andrea J. Singer, MD; Yamei Wang, PhD; Leny Pearman, PhD; John Caminis, MD; Jean-Yves Reginster, MD, PhD
Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis
Ruban Dhaliwal, MD, MPH; John Boxberger, PhD; Yamei Wang, PhD; Bruce Mitlak, MD; Ludovic Humbert, PhD; Neil Binkley, MD
Cost-Effectiveness of Sequential Abaloparatide/ Alendronate for US Women and Men at Very High Risk of Fracture: an Economic Evaluation Based on Network Meta-Analysis
Michaël Hiligsmann, Stuart Silverman, Andrea J Singer, Leny Pearman, Jake Mathew, Yamei Wang, John Caminis, Jean-Yves Reginster
Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis
Ruban Dhaliwal, MD, MPH; John Boxberger, PhD; Yamei Wang, PhD; Bruce Mitlak, MD; Ludovic Humbert, PhD; Neil Binkley, MD
Cost Effectiveness of Four Treatment Approaches for US Women and Men at Very High Risk of Osteoporotic Fractures
Mickael Hiligsmann, Stuart Silverman, Andrea J Singer, Leny Pearman, Yamei Wang, John N Caminis, and Jean-Yves Reginster
Abaloparatide is Chondroprotective in Posttraumatic Osteoarthritis
S.H. Landgrave, T. Ishii, R. Maynard, A. Wu, D. Godfrey, T. Manes, V. Butler, D. Villani, H. Hendesi, R. Frank, S. Iyer, K. Payne, D.J. Adams, L. Favazzo, B. Lanske, M.J. Zuscik
Abaloparatide Increases Bone Mineral Density in Regions Corresponding to Gruen Zones 1, 2, 6, and 7 in Postmenopausal Women With Osteoporosis
Neil P Sheth, Renaud Winzenrieth, Ludovic Humbert, Paul J Kostenuik, Yamei Wang, John Boxberger, Mathias P Bostrom
Effects of Abaloparatide or Placebo on Bone Mineral Density in Acetabular Regions Corresponding to DeLee and Charnley Zones in Postmenopausal Women with Osteoporosis
Neil P Sheth, Matias Bostrom, Renaud Winzenrieth, Ludovic Humbert, Leny Pearman, John Caminis, Yamei Wang, John Boxberger, Kelly Krohn
Cost Effectiveness of Four Treatment Approaches for US Women and Men at Very High Risk of Osteoporotic Fractures
Mickael Hiligsmann, Stuart Silverman, Andrea J Singer, Leny Pearman, Yamei Wang, John N Caminis, and Jean-Yves Reginster
Effects of Abaloparatide or Placebo on Bone Mineral Density in Acetabular Regions Corresponding to DeLee and Charnley Zones in Postmenopausal Women with Osteoporosis
Neil P Sheth, Matias Bostrom, Renaud Winzenrieth, Ludovic Humbert, Leny Pearman, John Caminis, Yamei Wang, John Boxberger, Kelly Krohn
Comparison of the Cost-Effectiveness of Sequential Treatment with Abaloparatide followed by Alendronate between US Women and Men at Increased Risk of Fracture
Mickaël Hiligsmann, Stuart Silverman, Andrea J. Singer, Leny Pearman, Yamei Wang, John Caminis, Jean-Yves Reginster
Bone Health Management in Elective Orthopedic Surgery
Karun Singla, Kyle J Jeray, Setareh A Williams, Yamei Wang, Leny Pearman, Nick Pyrih, Susan V Bukata, Ben Han
Cost-Effectiveness of Abaloparatide Followed by Alendronate in US Women and Men at High Risk of Osteoporotic Fractures
Michaël Hiligsmann, Stuart Silverman, Andrea J Singer, Leny Pearman, Yamei Wang, John Caminis, Jean-Yves Reginster
Real-World Cost-Effectiveness of Sequential Treatment with Abaloparatide followed by Alendronate in Men at High Risk of Fracture in the United States
Michaël Hiligsmann, Stuart Silverman, Andrea J Singer, Leny Pearman, Jake Mathew, Yamei Wang, John Caminis, Jean-Yves Reginster
Bone Health Management in Elective Orthopedic Surgery
Karun Singla, Kyle J Jeray, Setareh A. Williams, Yamei Wang, Leny Pearman, Nick Pyrih, Susan V Bukata, Ben Han
Abaloparatide Increases Bone Mineral Density in Regions Corresponding to Gruen Zones 1, 2, 6, and 7 in Postmenopausal Women With Osteoporosis
Neil P Sheth, Renaud Winzenrieth, Ludovic Humbert, Paul J Kostenuik, Yamei Wang, John Boxberger, Mathias P Bostrom
Effects of Abaloparatide or Placebo on Bone Mineral Density in Acetabular Regions Corresponding to DeLee and Charnley Zones in Postmenopausal Women with Osteoporosis
Neil P Sheth, Matias Bostrom, Renaud Winzenrieth, Ludovic Humbert, Leny Pearman, John Caminis, Yamei Wang, John Boxberger, Kelly Krohn
Comorbidities and Characteristics of Men with Subsequent Osteoporotic Fracture: A Real-world Observational Study
Ruban Dhaliwal, Bob Adler, Richard Lee, Yamei Wang, Setareh Williams, Nick Pyrih, Leny Pearman, John Caminis, Jeff Curtis
2022
Efficacy and Safety of Abaloparatide in Men with Osteoporosis
Edward Czerwinski, Jose Cardona, Rafal Plebanski,Chris Recknor, Tamara Vokes, Kenneth G Saag, Neil Binkley, E. Michael Lewiecki, Jonathan Adachi, Dorota Knychas, David Kendler, Eric Orwoll, Yinzhong Chen, Leny Pearman, Heather Li, Bruce Mitlak
Cost-Effectiveness of Sequential Treatment with Abaloparatide followed by Alendronate in US Men at Imminent Risk of Fracture
Mickaël Hiligsmann, Stuart Silverman, Andrea J Singer, Leny Pearman, Jake Mathew, Yamei Wang, John Caminis, Jean-Yves Reginster
Abaloparatide Increases Bone Mineral Density in Regions Corresponding to Gruen Zones 1, 2, 6, and 7 in Postmenopausal Osteoporotic Women
Neil P. Sheth, Renaud Winzenrieth, Ludovic Humbert, Paul J. Kostenuik, Yamei Wang, John I. Boxberger, Mathias P. Bostrom
Treatment Patterns in Women with Post-Menopausal Osteoporosis Using Abaloparatide: A Real-world Observational Study
Deborah T Gold, Tammy Beckett, Chad Deal, Andrew L James, Jacqueline M Kernaghan, Mahshid Mohseni, Abigail McMillan, Tom Bailey, Leny Pearman, John Caminis, Yamei Wang, and Setareh A. Williams
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
Ruban Dhaliwal, David Kendler, Kenneth Saag, Steven Ing, Andrea Singer, Robert Adler, Leny Pearman, Yamei Wang, Bruce Mitlak
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in Men at High Risk of Fractures in the United States
Michaël Hiligsmann, Stuart Silverman, Andrea J Singer, Leny Pearman, Jake Mathew, Yamei Wang , John Caminis, Jean-Yves Reginster
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
Ruban Dhaliwal, David Kendler, Kenneth Saag, Steven Ing, Andrea Singer, Robert Adler, Leny Pearman, Yinzhong Chen, Bruce Mitlak
Characterization of Men treated with Osteoanabolic Medication: A US Claims Database Study
Clayton LeBaume, Yamei Wang, Nick Pyrih, Leny Pearman, John Caminis, Setareh A. Williams
2021
Comparative Effects of Abaloparatide and Teriparatide on Cortical and Trabecular Bone
Arlt H, Lv Z-T, Hu D, Ominsky MS, Winzenreith R, Weiss R, Baron R, Lanske B, Besschetnova T
A Qualitative Study to Assess Patient Perspective of Osteoporosis Treatment
Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M
Heterogenicity in the Cortical Response to Abaloparatide and Teriparatide in the Proximal Femur by DXA-Based 3D Modeling
Winzenrieth R, Ominsky MS, Yang Y, Humbert L, Weiss R
Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Obesity
Garvey WT, Nikonova E, Wang Y, Schafer A
The Evaluation of Outcomes Following a Fragility Fracture in Real-world Setting
Singer AJ, Williams SA, Weiss RJ, Wang Y, Nichols H, Pyrih N
Biomechanical Computed Tomography Captures Older Men at High Risk of Hip Fracture Despite Low Fracture Risk Calculation by FRAX
Fu P, Chiang J, Keaveny TM, Bikle DD
Heterogenicity in the Cortical Response to Abaloparatide and Teriparatide in the Proximal Femur by DXA-Based 3D Modeling
Winzenreith R, Ominsky MS, Yang Y, Humbert L, Weiss R
An Evaluation of Treatment Patterns Following a Fragility Fracture in a Real-World Setting
Singer AJ, Williams SA, Weiss RJ, Wang Y, Nichols H, Pyrih N
Unmet Needs in Osteoporosis: Primary Care Perspectives from a National Advisory Board
Tough-DeSapri K, Arena JJ, Berman NR, Larkin L, Nikonova E, Smith A
Treatment Guidelines vs Treatment Reality: Current Management of Osteoporosis Patients at Very High Risk for Fracture
Diffenderfer BW, Williams SA, Wang Y, Pyrih N
Effect of Abaloparatide on Fracture Incidence and Bone Mineral Density in Postmenopausal Women with Osteoporosis at Highest Risk for Fracture
Clarke B, Kostenuik P, Wang Y, Tough-DeSapri K
Changes in Bone Microarchitecture Assessed by Trabecular Bone Score (TBS) with Abaloparatide in the ACTIVE and ACTIVExtend Trial
Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B
Treatment Patterns Following Abaloparatide Initiation: Data from Real-World Clinical Practice Settings
Gold DT, Pearman L, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, McMillan A, Bailey T, Wang Y, Williams SA
Abaloparatide as a Novel Chondroregenerative Therapy for Posttraumatic Osteoarthritis
Landgrave SH, Wu A, Ishi T, Maynard R, Godfrey D, Butler V, Iyer S, Lanske B, Zuscik MJ
Abaloparatide Promotes Bone Anabolism in Older Mice
Higsley S, Kolora LD, Butler V, Landgrave SP, Maynard R, Ishi T, Adams D, Lanske B, Zuscik M, Iyer S
Bone Anabolic Effects of a Novel, Orally Available Salt Inducible Kinase Inhibitor
Sato T, Andrade CD, Brooks DJ, Bouxsein ML, Zhao Y, Lanske B, Greenlee W, Weber PC, Kulp J, Wiswanathan U, Wein MN
2020
Abaloparatide Prevents Unloading-Induced Bone Loss in Adult Rats
Teguh DA, Nustad JL, Craven AE, Brooks DJ, Arlt H, Lanske B, Bouxsein ML
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
Dempster DW, Zhou H, Rao SD, Recknor C, Miller PD, Leder BZ, Annett M, Ominsky MO, Mitlak BH
Abaloparatide Enhances Fusion and Bone Formation in a Rabbit Spinal Arthrodesis Model
Hahn W, Kumagai H, Moore H, Koo A, Purdue E, Iyer S, Cunningham M
Abaloparatide Prevents Unloading-Induced Bone Loss in Adult Rats
Teguh DA, Craven AE, Nustad JL, Daniel J. Brooks DJ, Arlt H, Lanske B, Bouxsein ML
Characterization and Outcomes of Patients With a Fragility Fracture in an Integrated Healthcare Organization
Adams AL, Ryan DS, Li BH, Williams SA, Wang Y, Weiss R, Black DM
Characterization of Older Male Patients with a Fragility Fracture
Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR
Phase 1b Evaluation of Patient Experience with Abaloparatide Solid Microstructured Transdermal System in Postmenopausal Women with Low Bone Mineral Density
Miller PD, Weiss R, Williams SA, Annett M, Gabriel A, Schense J, Mitlak B
Phase 1B Evaluation of the Pharmacokinetics and Pharmacodynamics of Abaloparatide Solid Microstructured Transdermal System in Postmenopausal Women with Low Bone Mineral Density
Miller PD, Troy S, Weiss R, Annett M, Gabriel A, Schenese J, Mitlak B
Healthcare Resources Use in Patients with Fragility Fracture in an Integrated Healthcare Organization
Adams AL, Ryan DS, Li BH, Williams SA, Wang Y, Weiss R, Black DM
Phase 1b Evaluation of Patient Experience with Abaloparatide Solid Microstructured Transdermal System in Postmenopausal Women with Low Bone Mineral Density
Miller PD, Troy S, Weiss R, Annett M, Gabriel A, Schenese J, Mitlak B
A Real-World Study of the Patient Experience with Abaloparatide
Gold DT, Weiss R, Roberts J, Bailey T, Wang Y, James A, Mohseni M, Williams SA
Abaloparatide Prevents Unloading-Induced Bone Loss in Adult Rats
Teguh DA, Nustad JL, Craven AE, Brooks DJ, Arlt H, Lanske B, Bouxsein ML
Abaloparatide Enhances Fusion and Bone Formation in a Rabbit Spinal Arthrodesis Model
Moore H, Kumagai H, Hahn W, Koo A, Purdue E, Iver S, Cunningham M
Heterogenicity in the Cortical Response to Abaloparatide and Teriparatide in the Proximal Femur by DXA-Based 3D Modeling
Winzenrieth R, Ominsky MS, Yang Y, Humber L, Weiss R
Abaloparatide, PTHrP (1 34) Analog, Increases Lumbar, Total Hip and Femoral Neck BMD in Japanese Patients with Osteoporosis A phase III Randomized Clinical Trial in Japan (ACTIVE-J)
Matsumoto T, Sone T, Soen S, Sugimoto T, Tanaka S, Mihoya M, Inoue T
Abaloparatide, A Novel Selective Agonist for PTH/PTHrP Receptor, Effectively Improved Hip Geometry and Biomechanical Properties Assessed by Hip Structural Analysis in Elderly Osteoporotic Patients – Results of the Japanese Phase 3 Trial (ACTIVE-J)
Sone T, Oonaru K, Mihoya M, Inoue T, Matsumoto T
Abaloparatide Improves Bone Mass and Microarchitecture Without Increasing Resorption in Adult Rats Subjected to Hindlimb Unloading
Teguh DA, Craven AE, Nustad JL, Brooks DJ, Arlt H, Lanske B, Bouxsein ML
Abaloparatide is more effective than PTH in restoring bone formation and bone structural properties, but both agents similarly correct the impaired bone material properties and citrate content in mice with Type 1 Diabetes
Ozgurel SU, Sato A, McAndrews K, Halladay D, Cregor M, Solis AV, Gortazar A, Bellido T
Abaloparatide Promotes Bone Repair of Vertebral Defects in an Ovariectomized Rat Model of Osteoporosis
Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N
Abaloparatide is more effective than PTH in restoring bone formation and bone structural properties, but both agents similarly correct the impaired bone material properties and citrate content in mice with Type 1 Diabetes
Ozgurel SU, Sato A, McAndrews K, Halladay D, Cregor M, Solis AV, Gortazar A, Bellido T
Real-World Outcomes of Patients New to Osteoporosis Therapies
Williams SA, Weiss R, Wang Y, Cui L, Nichols H, Gernert A
Characterization of Older Male Patients with a Fragility Fracture
Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR
Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-based 3D Modeling
Winzenrieth R, Ominsky M, Wang Y, Humbert L, Weiss R
Differential Effects of Abaloparatide and Teriparatide on Cortical Volumetric BMD and Bone Strength Indices in the Proximal Femur by DXA-Based 3D Modeling
Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss R
Gender Disparities in Osteoporosis Screening & Management Among Older Adults
Ramachandran S, Williams SA, Weiss R, Wang Y, Zhang Y, Nsiah I
Characterization of Older Male Patients with a Fragility Fracture
Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR
Safety Assessment of Abaloparatide-Solid Microstructured Transdermal System for the Treatment of Osteoporosis in Hra:(NZW) SPF Rabbits
Li G, Gelow K, Atkari K, Dandekar D, Troy S